Sign In
Buy IOVA
$3.79
-0.310 (-7.56%)
At Close: Jun 03, 2026
Iovance Biotherapeutics: Preparing For Volatility Around Lifileucel's Upcoming PDUFA Date
04:59pm, Friday, 19'th Jan 2024
Iovance Biotherapeutics is preparing for the extended FDA deadline to determine the approval of lifileucel for advanced melanoma treatment. The FDA has put a clinical hold on the company's Phase II st
Iovance (IOVA) Surges More Than 150% in 3 Months: Here's Why
01:32pm, Monday, 15'th Jan 2024
Iovance's (IOVA) surges on the anticipated FDA approval for its lead pipeline drug as the first individualized, one-time cell therapy for certain patients with melanoma.
4 Best Breakout Stocks to Buy for Stellar Returns
07:31am, Friday, 12'th Jan 2024
Universal Stainless & Alloy Products (USAP), Lakeland Industries (LAKE), NGL Energy Partners (NGL) and Iovance Biotherapeutics (IOVA) have been selected as the breakout stocks for today.
3 Biotech Bull Cases To Consider In 2024 - And 2 Wildcard Recommendations
02:12pm, Friday, 29'th Dec 2023
The biotech sector is finishing 2023 on a high after a difficult couple of years, buoyed by Big Pharma M&A activity. The SPDR® S&P Biotech ETF has been soaring as a result of the M&A spree. Despite a
Why Iovance Biotherapeutics Stock Popped Today
05:59pm, Thursday, 28'th Dec 2023
Iovance jumped as investors assessed the fallout of yesterday's clinical hold on its IOV-LUN-202 clinical trial following a patient's death. The company is pausing enrollment for new patients during t
Iovance (IOVA) Falls After Clinical Update on Lung Cancer Drug
12:47pm, Thursday, 28'th Dec 2023
Iovance (IOVA) is likely to pause enrollment in the phase II IOV-LUN-202 study evaluating its tumor infiltrating lymphocyte therapy, LN-145, for treating non-small cell lung cancer. Stock declines.
Why Iovance Biotherapeutics Stock Is Crashing Today
11:47am, Wednesday, 27'th Dec 2023
The U.S. FDA placed a clinical hold on Iovance's study evaluating LN-145 TIL in treating non-small-cell lung cancer. This clinical hold came after a patient in the study died.
Iovance Biotherapeutics faces setback as FDA imposes clinical hold on lung cancer trial
10:48am, Wednesday, 27'th Dec 2023
Iovance Biotherapeutics (NASDAQ:IOVA) shares plunged after it revealed that the FDA has imposed a clinical hold on its lung cancer therapy trial following the death of a patient. The patient's death i
Options Traders Target Plunging Biotech Stock
10:37am, Wednesday, 27'th Dec 2023
Iovance Biotherapeutics Inc (NASDAQ:IOVA) was last seen 17.8% lower to trade at $7.31, one of the worst stock's on the Nasdaq today.
Iovance stock drops 23% in premarket trades after it halts cancer drug trial
08:59am, Wednesday, 27'th Dec 2023
Iovance Biotherapeutics Inc.'s stock IOVA, +6.59% fell 22.6% in premarket trading on Wednesday after the cancer therapy company said the U.S. Food and Drug Administration placed a clinical hold on its
Iovance's IOVA stock price suffers a harsh reversal: buy the dip?
08:36am, Wednesday, 27'th Dec 2023
Iovance Biotherapeutics (NASDAQ: IOVA) stock price suffered a harsh reversal on Wednesday after the company suffered a major setback. The stock, which has been in a strong uptrend, crashed by more tha
Iovance Stock Plunges as FDA Puts Hold on Lung Cancer Study After Patient Death
07:50am, Wednesday, 27'th Dec 2023
The FDA places a clinical hold on Iovance's trial of a lung cancer therapy after the company reports a death potentially related to the treatment.
US FDA places clinical hold on Iovance's lung cancer treatment trial
07:15am, Wednesday, 27'th Dec 2023
Iovance Biotherapeutics said on Wednesday that the U.S. Food and Drug Administration has placed a clinical hold on its trial on a therapy for a type of lung cancer.
Iovance Biotherapeutics: The Easiest Money May Have Been Made, But Approval Does Seem Likely
01:25pm, Tuesday, 12'th Dec 2023
IOVA's marketing application for lifileucel is still awaiting approval from the FDA, with a new decision date set for February 24, 2024. Despite the delay, IOVA suggests a possible early approval in J
Better Growth Stock: Viking Therapeutics or Iovance Biotherapeutics?
08:45am, Tuesday, 12'th Dec 2023
Small to mid-cap biotechs are known for their extreme volatility, and sometimes, market-crushing returns on capital. Iovance Biotherapeutics and Viking Therapeutics are two of the most popular stocks
